7CI.F Cronos Group Inc
- Market cap
- EUR 1.13B
- P/E
- 22.0x
- P/B
- 1.17x
- ROE
- 7.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 7CI.F undervalued?
Graham number7CI.F trades 7.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cronos Group Inc fundamental analysis
No fundamental analysis for Cronos Group Inc yet.
Cronos Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cronos Group Inc
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Full company profileCronos Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cronos Group Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 3.25M | 11.5M | 23.8M | 46.7M | 74.4M | 91.9M | 87.2M | 118M | 147M | 216M |
| Gross Profit | - | 5.75M | 8.27M | -17.9M | -25.8M | -17.5M | 12.0M | 11.9M | 25.2M | 62.8M | 107M |
| Operating Income | - | -1.68M | -13.3M | -116M | -179M | -197M | -116M | -79.9M | -59.5M | -19.5M | 20.1M |
| EBITDA | - | 3.11M | -11.5M | 1.17B | -66.0M | -382M | -103M | -71.8M | -50.2M | -5.27M | 35.8M |
| Net Income | - | 1.98M | -13.9M | 1.17B | -73.1M | -396M | -169M | -74.0M | 41.1M | -9.45M | 79.5M |
| EPS | - | 0.01 | -0.08 | 3.34 | -0.20 | -1.06 | -0.44 | -0.19 | 0.11 | -0.02 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | - | 80.3M | 192M | 2.09B | 1.93B | 1.40B | 1.21B | 1.14B | 1.17B | 1.20B | 1.20B |
| Total Liabilities | - | 11.7M | 36.3M | 341M | 218M | 63.5M | 72.0M | 44.0M | 55.3M | 54.2M | 73.4M |
| Shareholders' Equity | - | 68.7M | 155M | 1.75B | 1.71B | 1.34B | 1.14B | 1.10B | 1.06B | 1.09B | 1.07B |
| Cash & Short-term Investments | - | 7.32M | 24.0M | 1.20B | 1.08B | 887M | 765M | 669M | 859M | 792M | 411M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.48M | -4.28M | -7.52M | -131M | -145M | -154M | -88.9M | -42.8M | 18.8M | 25.9M | 92.3M |
| Capital Expenditure | 0.00 | 32.9M | 88.3M | 38.7M | 31.4M | 11.1M | 3.45M | 3.42M | 13.2M | 26.1M | 18.3M |
| Free Cash Flow | - | -38.4M | -91.4M | -169M | -178M | -166M | -94.0M | -46.3M | 5.69M | -190K | 74.1M |
| Ratios | |||||||||||
| ROE | - | 2.9% | -9.0% | 66.7% | -4.3% | -29.6% | -14.8% | -6.7% | 3.9% | -0.9% | 7.4% |
| ROA | - | 2.5% | -7.3% | 55.8% | -3.8% | -28.3% | -13.9% | -6.5% | 3.5% | -0.8% | 6.6% |
| Net Profit Margin | - | 61.0% | -120.8% | 4,911.6% | -156.5% | -532.2% | -183.6% | -84.8% | 34.9% | -6.4% | 36.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cronos Group Inc dividends
Cronos Group Inc has not paid dividends in the last 9 fiscal years.
Who owns Cronos Group Inc
- Insiders 49.42%
- Institutions 15.79%
- Public & others 34.79%
- Shares outstanding 366M
- Free float 186M
Cronos Group Inc company profile
- Company name
- Cronos Group Inc
- Ticker
- 7CI.F
- ISIN
- CA22717L1013
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 610
- Fiscal year end
- December
- Address
- 4491 Concession Road 12, Stayner, ON, Canada, L0M 1S0
- Phone
- 416 504 0004
- Website
- thecronosgroup.com
About Cronos Group Inc
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Cronos Group Inc management
10- Mr. Michael Ryan Gorenstein J.D.President, CEO & Chairman · born 1987
- Ms. Anna ShlimakChief Financial Officer · born 1986
- Ms. Shannon BuggySenior VP & Global Head of People · born 1970
- Mr. Jeffrey David JacobsonChief Growth Officer · born 1986
- Mr. Adam WagnerGeneral Manager of Cronos Israel · born 1983
- Mr. Jared Matthew KenostVP, Principal Accounting Officer & Controller
- Mr. Harrison AaronSenior Director of Investor Relations & Corporate Development
- Mr. Terry Gregory-Joseph DoucetGeneral Counsel & Corporate Secretary · born 1990
- Mr. Arye WeigensbergSenior VP and Head of Research & Development · born 1983
- Christopher MartensGeneral Manager